Neoglycopolymers of polyacrylamide backbone conjugated with varying densities of Galα1−3Galβ1−4Glcβ trisaccharide epitopes (α-Gal epitopes) were designed and synthesized to study the inhibition of the
binding of human natural anti-Gal antibodies to either α-Gal-containing glycoproteins or α-Gal antigens on
the surface of mammalian cells. An inhibition ELISA using mouse laminin and a flow cytometry assay using
pig kidney cells (PK15) were established to determine the binding affinity of the synthesized polymers. In
comparison to the α-Gal monomer (Galα1−3Galβ1−4GlcNHAcβ), the α-Gal polymers dramatically enhanced
the inhibition of human anti-Gal antibodies (IgG, IgM, and IgA) binding to mouse laminin or mammalian
cells. Increases of 7.8 × 103- and 5.0 × 104 -fold in inhibitory potential of polymer 7C to IgA and IgM (with
IC50s of 7.0 and 5.6 nM respectively) were observed over the monomer in inhibition ELISA. The results also
indicated that binding enhancement of α-Gal polymers is greater for anti-Gal IgA and IgM than for IgG. Such
amplified binding differences among the three anti-Gal isotypes can be utilized to selectively inhibit or remove
a particular isotype of anti-Gal antibodies. Moreover, it was demonstrated through the flow cytometry assay
that certain α-Gal polymers are effective in inhibition of anti-Gal antibody (in human serum) binding to pig
kidney (PK15) cells. Thus, such synthetic carbohydrate polymers may find practical applications in cell
xenotransplantations.